bariatric surgery vs semaglutide Outperforms GLP-1s in Weight Loss Revisional Metabolic and Bariatric Surgery

This data suggests greater weight loss, 1-3 pounds on average, per month with tirzepatide (active ingredient in Mounjaro and Zepbound) over semaglutide (active ingredient in Ozempic and Wegovy)

The long-term benefits include sustainable weight management, enhanced cardiovascular health, and a reduced risk of obesity-related complications such as diabetes and heart disease

OLIMP LABORATORIES Sp

A search on PubMed returns many papers on rodents and cell models, and reviews on PubMed Central describe it as a possible therapy rather than a proven one

Archived from the original on December 12, 2012

Lack of FDA regulation: This raises safety and consistency concerns